Aeglea BioTherapeutics, Inc. announced that effective May 16, 2023, the employment Of Mr. Jeffrey Goldberg, the President and Chief Executive Officer of the company was terminated.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.67 USD | -2.72% | -3.66% | +56.46% |
15/05 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
13/05 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.46% | 170.98Cr | |
+18.72% | 12TCr | |
+14.19% | 11TCr | |
-4.93% | 2.42TCr | |
+3.23% | 2.28TCr | |
-10.44% | 1.8TCr | |
-41.74% | 1.64TCr | |
-13.31% | 1.64TCr | |
+2.44% | 1.36TCr | |
+27.89% | 1.17TCr |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Aeglea Biotherapeutics, Inc. Announces the Termination of Jeffrey Goldberg as Chief Executive Officer